Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psma adc
- Development stage
- Phase 2
- Lead developer
- Lantheus
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PSMA ADC is an investigational antibody-drug conjugate designed to target prostate-specific membrane antigen (PSMA), a cell surface protein highly expressed on prostate cancer cells. The drug consists of a fully human IgG1 monoclonal antibody directed against PSMA, conjugated via a valine–citrulline linker to the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule-disrupting agent. Upon binding to PSMA-expressing cells, the ADC is internalized and MMAE is released intracellularly, leading to cell cycle arrest and apoptosis. Developed primarily for metastatic castration-resistant prostate cancer (mCRPC), PSMA ADC has demonstrated selective antitumor activity in preclinical models and has undergone phase 1 and phase 2 clinical trials in patients with advanced or chemotherapy-refractory prostate cancer[1][3][4][6][9].
- Other names
- Prostate-specific membrane antigen antibody-drug conjugatePSMA antibody-drug conjugate
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on psma adc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psma adc.